01548 GENSCRIPT BIO
- 10.920
- -0.080-0.73%
GENSCRIPT BIO News
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Genscript Bio (01548) issued 0.0108 million shares according to the restricted stock award plan.
Genscript Bio (01548) announced that on November 11, 2024, in accordance with the agreement dated August 2, 2021...
GenScript Biotech Sets Up New Operations and Logistics Hub in Sydney, Australia
[Brokerage Focus] Bocom Intl believes that the prospects of domestic CXOs' overseas business are mixed after Trump's election.
Jingu Financial News | Bocom Intl research reports indicate that the outlook for domestic CXO overseas business after Trump's election is mixed: 1) a Republican-controlled Congress may advocate 'America First' in the pharmaceutical supply chain; 2) the fate of the IRA signed by the Biden administration under the Trump government is uncertain; 3) Trump may give more managerial responsibilities to Robert Kennedy in the medical health field, who opposes vaccines and claims to extensively reform the American medical health system, which could bring certain pressure to downstream customers of CXO; 4) Trump's tariff policy and overall loose fiscal policy stance may lead to subsequent inflation.
This week, Hong Kong stocks' star stocks | Expectations of top brokerages merging are hyped! A-share trading is hot! China-affiliated brokerage stocks collectively soaring; shanghai electric group skyrocketed by 62% in one week, officially announcing merg
This week, the Hong Kong stock market ended four consecutive weeks of decline, with daily levels still fluctuating. The Hang Seng Index rose by 1.08% to 20,728.19 points; during the same period, the Hang Seng Tech Index rose by 4.11% to 4,668.26 points; the Hang Seng China Enterprises Index rose by 1.62% to 7,461.44 points.
Hong Kong stock market retreats from its high levels, with the Hang Seng Index and the H-share Index both falling by over 1%; the real estate and brokerage sectors decline, Sunac drops more than 9%, Citic Securities falls by nearly 6%.
Network technology stocks decline, NetEase-S drops by 5.61%, Meituan-W drops by 4.05%; Securities and brokerage stocks weaken, CSC drops by 5.45%, China International Capital Corporation drops by 4.34%; Coal industrial concept stocks weaken, China Coal Energy drops by 4.22%, Kinetic Dev drops by 3.18%.
Genscript Bio (01548): Legend Biotech announces the latest data on the minimal residual disease (MRD) negativity rate related to the phase 3 CARTITUDE-4 trial.
Genscript Bio (01548) announced in a statement that on November 5, 2024, legend biotech will showcase...
Insiders At Genscript Biotech Sold US$12m In Stock, Alluding To Potential Weakness
The first batch of pharmaceutical fund's third quarter report is released! Shareholding in US stocks reduced, while increasing holdings in Hong Kong stocks and A-shares.
The first batch of fund managers exposed in the third quarter medical investment strategy, significantly increased the proportion of innovative drugs, especially the position of Hong Kong-listed innovative drugs with greater flexibility.
Abnormal movement hits the CRO concept in the morning, driven by innovative drug policies and expectations of Fed rate cuts, Pharmaron and Tigermed both rose more than 7%.
CRO concept rose in the morning, as of the time of publication, Frontage Holdings increased by 8.45%, Pharmaron increased by 7.64%, Tigermed increased by 7.99%, and Joinn Laboratories increased by 5.59%.
HK Stock Market News | Genscript Bio (01548) fell nearly 5% in the afternoon, Genscript Financials no longer consolidated with legend biotech. The company clarifies the rumors of selling the cell business.
genscript bio (01548) fell nearly 5% in the afternoon, as of the time of publication, down 4.58%, at 12.08 Hong Kong dollars, with a turnover of 87.4963 million Hong Kong dollars.
[Brokerage Focus] Bocom Intl maintains a buy rating on Kingsoft (01548), indicating that it will enter the profit range comprehensively starting from 2024.
Golden Finance News | Bocom Intl released a research report stating that Genscript Bio (01548) announced a decrease in the voting rights proportion over Legend Biotech from over 50% to 47.56%, while also losing the power to cast majority votes at the Legend Biotech shareholders' meeting, as well as the power to unilaterally manage Legend's finances and operational policies. Therefore, the company has decided to deconsolidate Legend from October 18, 2024, and treat it as an investment in an associate. On the deconsolidation date, the company will reflect the fair market value of its investment in Legend Biotech based on the market value of the Legend Biotech shares it holds (closing market cap approximately 79.
Bocom Intl: Rated Genscript Bio (01548) as 'buy' with a target price of 28.75 Hong Kong dollars.
bocom intl lowers Kingsley Bio's revenue forecast for 2024-26 to $1.06 billion/ $0.71 billion/ $0.84 billion.
Hong Kong stocks closed (10.22) | Hang Seng Index rose by 0.1%, autos generally rose, zte (00763) dropped more than 8% after earnings.
Hong Kong stocks rebounded slightly today, with all three major indices closing slightly higher. There was a temporary dive in the afternoon leading to a decline.
Express News | Legend Biotech Shares Jump 8.3% Premarket After Key Shareholder Resolves to Deconsolidate Co and Its Units
Express News | Genscript Bio will no longer consolidate Legend Biotech's financials, will the cell business be adjusted? The company responded in this way.
Hong Kong stock market midday review | The three major indices are all rising! The technology index rose more than 1%, with autos and nuclear power leading the gains, li auto inc rose more than 7%, cgn mining surged more than 21%.
Network technology stocks rose across the board, with Sensetime-W up 4.40%, Meituan-W up 3.75%; digital health stocks performed well, with Mindray Medical up 15.28%, jd health up 3.99%; securities and brokerage stocks rallied, china merchants rose 5.13%, swhy rose 4.74%.
Hong Kong stock market anomaly | CRO concept stocks collectively rise. The segmented production trial work plan for biological products will be released in the near future.
CRO concept stocks collectively rose, as of the time of publication, frontage (01521) rose by 13.79%, to 0.66 Hong Kong dollars; genscript bio (01548) rose by 4.75%, to 12.36 Hong Kong dollars; pharmaron (03759) rose by 3.68%, to 15.2 Hong Kong dollars.
Genscript Bio (01548.HK) will deconsolidate Legend Holdings and treat it as an associate investment, expecting to confirm a one-time tax-free income.
Genscript Bio (01548.HK) announced that Legend Biotech (LEGN.US) has irrevocably notified the custodian that it has decided to no longer exercise its full power of attorney, despite the existence of previous certificates. The custodian's ability to grant any full power of attorney has been terminated. As of September 30, Genscript actually owns 47.56% of Legend Biotech's issued share capital. After the termination of the full power of attorney, Genscript has lost the power to unilaterally manage the financial and operational policies of the Legend Group at the majority shareholder meeting. Therefore, Genscript has decided to deconsolidate the Legend Group.
Genscript Bio (01548): The amendment of the deposit agreement led to the termination of the merger with Legend Biotech Co., Ltd. and its subsidiaries.
Genscript Bio (01548) announced that on October 18, 2024 (New York time), Legend...
Analysis
Price Target
No Data
No Data